AAP
VYGR icon

Ardsley Advisory Partners’s Voyager Therapeutics VYGR Stock Holding History

Ardsley Advisory Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,000
Closed -$415K – 174
2017
Q4 		$415K Buy
+25,000
New +$429K 0.05% 97

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ardsley Advisory Partners's VYGR Position: Q1 2018 in Review

Ardsley Advisory Partners sold out of Voyager Therapeutics (VYGR) in Q1 2018, closing a stake of 25,000 shares — an estimated $415K sold.

Ardsley Advisory Partners first reported a position in VYGR in Q4 2017 and held it in 1 quarter. The position peaked at $415K in Q4 2017. 108 funds tracked by Wall St. Rank hold VYGR as of Q1 2018.

  • Ardsley Advisory Partners reported no remaining Voyager Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ardsley Advisory Partners sold 25,000 Voyager Therapeutics shares in Q1 2018, an estimated $415K.
  • Ardsley Advisory Partners first reported a position in Voyager Therapeutics in Q4 2017 and held it in 1 quarter.
  • Ardsley Advisory Partners's Voyager Therapeutics position peaked at $415K in Q4 2017.
  • 108 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2018.

Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.